Peer-reviewed veterinary case report
Comparing two drug combos with piroxicam for dog bladder cancer
By Allstadt, S D et al.·Published in Journal of veterinary internal medicine·2015·Department of Veterinary Surgical and Radiological Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
- Species:
- dog
Plain-English summary
A group of 50 dogs with transitional cell carcinoma (TCC), a type of bladder cancer, were treated with either mitoxantrone or carboplatin along with piroxicam, a common anti-inflammatory medication. The goal was to see if one treatment worked better than the other in slowing the cancer's progression. Unfortunately, neither treatment showed a significant advantage; both groups had similar outcomes, with only a few dogs showing partial improvement. Dogs with tumors in the prostate had shorter survival times compared to those with tumors in other locations. Overall, the study found that both treatment options were comparable in effectiveness.
People also search for: dog bladder cancer treatment · transitional cell carcinoma in dogs · piroxicam for dog cancer · mitoxantrone vs carboplatin for dogs
Abstract
BACKGROUND: Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response. HYPOTHESIS/OBJECTIVES: To determine if the progression-free interval (PFI) of dogs with TCC treated with mitoxantrone and piroxicam was different than that of dogs receiving carboplatin and piroxicam. The hypothesis was that the efficacy of mitoxantrone is no different from carboplatin. ANIMALS: Fifty dogs with TCC without azotemia. METHODS: Prospective open-label phase III randomized study. Either mitoxantrone or carboplatin was administered every 3 weeks concurrently with piroxicam with restaging at 6-week intervals. Twenty-four dogs received carboplatin and 26 received mitoxantrone. RESULTS: Response was not different between groups (P = .56). None of the dogs showed complete response. In the mitoxantrone group, there were 2 (8%) partial responses (PR) and 18 (69%) dogs with stable disease (SD). In the carboplatin group, there were 3 PR (13%) and 13 (54%) dogs with SD. The PFI was not significantly different between groups (mitoxantrone = 106 days; carboplatin = 73.5 days; P = .62; hazard ratio 0.86; 95% confidence interval 0.47-1.56). Dogs with prostatic involvement experienced a shorter survival (median, 109 days) compared to dogs with urethral, trigonal, or apically located tumors; this difference was significant (median 300, 190, and 645 days, respectively; P = .005). CONCLUSIONS AND CLINICAL IMPORTANCE: This study did not detect a different in outcome in dogs with TCC treated with either mitoxantrone or carboplatin in combination with piroxicam.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25619518/